Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
复制标题
DOI：
10.1358/dot.2020.56.4.3127026
复制
发表时间：
2020-04
期刊：
影响因子：
--
通讯作者：
Kamdar M
中科院分区：
文献类型：
--
作者：
Amaya ML;Jimeno A;Kamdar M
弥漫性大B细胞淋巴瘤（DLBCL）是成人最常见的非霍奇金淋巴瘤（NHL），约占成人NHL病例的30%。新诊断的患者接受利妥昔单抗联合含蒽环类药物的化疗，但大量患者在初始治疗后复发。针对复发性淋巴瘤的新策略正在开发中，其中抗体-药物缀合物（ADC）目前处于临床试验中。Polatuzumab vedotin是一种新型ADC，可与通常表达的B细胞抗原CD 79 b结合，并递送单甲基奥瑞他汀E，一种具有抗微管蛋白活性的小分子。Polatuzumab vedotin联合苯达莫司汀和利妥昔单抗（BR）已在美国和欧盟获批。用于不适合移植的复发性或难治性DLBCL患者。这些批准是基于接受polatuzumab vedotin + BR或BR单药治疗的患者的随机化研究，其中polatuzumab vedotin + BR组的完全缓解率为40%，BR组为18%。该治疗最常见的不良事件是血细胞减少和周围神经病变。
Diffuse large B-cell lymphoma (DLBCL) is the most common non Hodgkin lymphoma (NHL) in adults, and it accounts for about 30% of adult NHL cases. Newly diagnosed patients are treated with rituximab in combination with anthracycline-containing chemotherapy, but a significant number of patients relapse after initial treatment. New strategies for relapsed lymphomas are in development among which antibody–drug conjugates (ADCs) are currently in clinical trials. Polatuzumab vedotin is a novel ADC which binds to the commonly expressed B-cell antigen CD79b, and it delivers monomethyl auristatin E, a small molecule with anti-tubulin activity. Polatuzumab vedotin in combination with bendamustine and rituximab (BR) has been approved in the U.S. and the E.U. for use in patients with relapsed or refractory DLBCL ineligible for transplant. These approvals were based on a randomized study of patients treated with either polatuzumab vedotin plus BR or BR alone, where complete response was 40% in the polatuzumab vedotin + BR group versus 18% in the BR group. The most common adverse events of this treatment were cytopenias and peripheral neuropathy.
登录
查看更多内容
影响因子：
24.7
作者：
Morschhauser, Franck;Flinn, Ian W.;Sharman, Jeff
通讯作者：
Sharman, Jeff
影响因子：
45.3
作者：
Bartlett, Nancy L.;Wilson, Wyndham H.;Leonard, John P.
通讯作者：
Leonard, John P.
影响因子：
45.3
作者：
Scott, David W.;Mottok, Anja;Gascoyne, Randy D.
通讯作者：
Gascoyne, Randy D.
影响因子：
11.2
作者：
Polson, Andrew G.;Calemine-Fenaux, Jill;Ebens, Allen
通讯作者：
Ebens, Allen
影响因子：
20.3
作者：
Gutierrez-Garcia, Gonzalo;Cardesa-Salzmann, Teresa;Lopez-Guillermo, Armando
通讯作者：
Lopez-Guillermo, Armando